Exelixis

Exelixis, Inc. is a biopharmaceutical company founded in 1994 by a team of scientists, including Corey Goodman, Spyros Artavanis-Tsakonas, and Pamela Bjorkman. Headquartered in Alameda, California, Exelixis is dedicated to developing innovative small molecule therapies for cancer treatment. The company focuses on discovering drugs that target specific pathways involved in cancer formation, growth, and metastasis. Exelixis markets several products, including Cometriq (cabozantinib), approved for medullary thyroid cancer, and Cabometyx (cabozantinib), which is used for advanced renal cell carcinoma and hepatocellular carcinoma. The company is also advancing a pipeline of promising candidates, such as zanzalintinib, XB002, XL102, and CBX-12, aimed at treating advanced or metastatic solid tumors. Exelixis collaborates with other biopharmaceutical companies to enhance its research and commercialization efforts.